CareLit Fachartikel

Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)

M Kreuter, B Crestani, T Ogura, K Pelling, C Coeck, M Quaresma, M Kaye · Pneumologie · 2016 · Heft 02

Dokument
1115641
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
M Kreuter, B Crestani, T Ogura, K Pelling, C Coeck, M Quaresma, M Kaye
Ausgabe
Heft 02 / 2016
Seiten
–
Erschienen: 2016-02-09 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0036-1571997

Zusammenfassung

Introduction: The INPULSIS® trials assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with idiopathic pulmonary fibrosis. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo in both trials. Patients who completed the 52-week treatment period and follow-up visit 4 weeks later (n = 807) could receive open-label nintedanib in an extension trial. Aim: To assess the long-term efficacy and safety of nintedanib. Methods: Patients treated with placebo in the INPULSIS® trials initiated treatment with nintedanib in the extension; patie…

Schlagworte

Nintedanib Patients Extension Inpulsis Trials Trial Treated Continuing Efficacy Safety Initiated Duration Pneumologie